New Treatment Option Combining Protease Inhibitor and Boosting Agent Reduces the Number of Pills Required to Manage HIV
Janssen Inc. announced today that PREZCOBIX™ (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. It is the first HIV treatment option available to patients that provides boosted darunavir in a single tablet.
"We have seen incredible advancements with HIV treatment in the last couple of decades, but managing treatment schedules remains a challenge for patients," says Dr. Sharon Walmsley, Director of Clinical Research, Immunodeficiency Clinic, Toronto Hospital, UHN and Professor, University of Toronto, Department of Medicine. "PREZCOBIX™ is an important new option in HIV treatment as it helps physicians simplify medical regimes and reduces the burden often associated with taking multiple pills daily."
Patients with conditions like HIV that require either taking medication more than once a day or taking multiple medications may find it difficult to adhere to their treatment schedules. Research has shown that reducing the number of pills given to patients living with HIV can significantly improve adherence.
New two-dose HIV vaccine strategy shows promise for stronger immune response